Table 1 Patient background, and incidents and rates of complications
All | Control | Bridging | P value | |
|---|---|---|---|---|
Biopsy, n | 1307 | 1281 | 26 | |
Patients, n | 1134 | 1109 | 25 | |
Age (years) | 70 (65, 74) | 70 (65, 70) | 74 (71, 76) | <0.001 |
PSA (ng/mL) | 7.8 (5.4, 13.5) | 7.8 (5.4, 13.5) | 10.5 (6.8, 14.6) | 0.099 |
Diabetes, n | 131 (13%) | 124 (11%) | 7 (27%) | 0.011 |
Hypertension, n | 423 (32%) | 411 (37%) | 12 (46%) | 0.141 |
Frequencies of biopsy | 1 (1, 2) | 1 (1, 2) | 1 (1, 1) | 0.970 |
Number of cores | 10 (10, 12) | 10 (10, 12) | 10 (10, 10) | 0.523 |
Prostate cancer, n | 607 (46%) | 594 (46%) | 13 (50%) | 0.843 |
Use of any antithrombotic agents (any), n | 294 (23%) | 268 (21%) | 26 (100%) | <0.001 |
Low dose aspirin | 191 (15%) | 11 (42%) | ||
Warfarin | 52 (4.1%) | 19 (73%) | ||
Clopidogel/ticlodipine | 37 (2.9%) | 7 (27%) | ||
NOAC | 3 (0.2%) | 1 (3.8%) | ||
Reason for antithrombotic agents use, n | ||||
Atrial fibrillation (Af) | 157 (12%) | 139 (11%) | 18 (69%) | |
Myocardial infarction (MI) | 52 (4.0%) | 46 (3.6%) | 6 (23%) | |
Others | 86 (6.6%) | 84 (6.6%) | 2 (8%) | |
CHADS2 score | 0 (0, 0) | 0 (0, 1) | 2 (0, 2) | <0.001 |
Complications | ||||
All events, n | 118 (9.0%) | 106 (8.3%) | 9 (35%) | <0.001 |
Grade 1 or 2 | 106 (8.1%) | 95 (7.4%) | 8 (31%) | |
Grade 3 | 12 (0.9%) | 11 (0.9%) | 1 (3.8%) | |
Bleeding related events, n | 64 (4.9%) | 57 (4.4%) | 7 (27%) | <0.001 |
Grade 1 or 2 | 57 (4.4%) | 51 (4.0%) | 6 (23%) | |
Grade 3 | 7 (0.5%) | 6 (0.5%) | 1 (3.8%) | |
Urinary tract infection, n | 17 (1.3%) | 15 (1.2%) | 2 (7.7%) | 0.043 |
Others, n | 34 (2.6%) | 34 (2.7%) | 0 (0%) | 1.000 |
Thrombotic events, n | 0 (0%) | 0 (0%) | 0 (0%) |